Investors are navigating a market that feels split in two. Artificial intelligence spending remains strong, semiconductor earnings are rising, and major companies continue to invest billions into infrastructure. At the same time, oil prices are climbing, freight costs remain a concern, and global trade routes are under pressure.
That backdrop is helping certain stocks stand out. Companies with clear growth plans, strong numbers, regulatory progress, or expanding demand are drawing fresh attention. Based on the upside figures provided in the source material, these 10 up-and-coming stocks are among the names investors are watching closely.
Why These Stocks Are in Focus
This list includes biotech companies nearing key FDA milestones, healthcare businesses benefiting from long-term demand, industrial firms improving leadership, and AI-linked companies building the next wave of digital infrastructure.
These are not random speculative names. Each company has a visible business catalyst that could shape performance in the months ahead.
10. Belite Bio Could Be Near a Major Breakthrough
Ticker: NASDAQ: BLTE
Average Upside Potential: 29.31%
Belite Bio is focused on treatments for retinal disease and metabolic conditions. On April 21, the company began a rolling NDA submission to the FDA for tinlarebant, a treatment candidate for Stargardt disease type 1.
Stargardt disease is a rare inherited eye disorder that can lead to legal blindness. The company expects to complete the filing by Q2 2026. The application is supported by Phase 3 DRAGON trial data, which show the drug could slow retinal degeneration.
Belite is also preparing its commercial operations for a possible 2027 launch, making this a stock closely tied to regulatory progress.
9. PACS Group Is Expanding in a High-Demand Healthcare Market
Ticker: NYSE: PACS
Average Upside Potential: 34.43%
PACS Group operates one of the largest post-acute healthcare platforms in the United States. The company supports more than 320 facilities across 17 states and serves over 31,700 patients daily.
On April 27, PACS appointed Carey P. Hendrickson as Chief Financial Officer. He brings nearly 40 years of experience and previously served as CFO of US Physical Therapy, where he oversaw financial operations for nearly 800 clinics across 44 states.
The leadership move comes as PACS continues to scale its national footprint.
8. Amentum Is Quietly Playing a Key Role in Space Growth
Ticker: NYSE: AMTM
Average Upside Potential: 37.80%
Amentum is gaining attention because of its involvement in NASA’s Artemis II mission. On April 13, the company highlighted work that included ground systems operations, operation of the Crawler Transporter, launch system integration, and mission testing support.
The company also assisted with the recovery of the Orion spacecraft after mission operations. Amentum’s business is built around engineering and technology services, giving it exposure to long-cycle government and aerospace contracts.
7. ABIVAX Has Cash and a Late-Stage Drug Catalyst
Ticker: NASDAQ: ABVX
Average Upside Potential: 37.83%
ABIVAX develops treatments for chronic inflammatory diseases. Its lead candidate, obefazimod, is being studied for ulcerative colitis.
The company reported FY2025 results on March 23 and showed strong liquidity after a $700.3 million public offering completed in July 2025. It ended the year with €530.4 million in cash and short-term investments, which are expected to fund operations into Q4 2027.
Its Phase 3 ABTECT UC trial remains the major focus. Topline results are expected in late Q2 2026, with a potential NDA filing in Q4 2026 if the data is positive.
6. Core Scientific Is Transforming Into an AI Infrastructure Story
Ticker: NASDAQ: CORZ
Average Upside Potential: 38.46%
Core Scientific has become a closely watched transition story. On April 27, the company announced a major expansion at its Pecos, Texas, campus.
The site is targeting 1.5 GW of gross power capacity, with around 1.0 GW expected to be leasable. The company is shifting the campus from bitcoin mining use toward AI and high-density computing infrastructure.
Construction is already underway, and the first data hall is expected in early 2027. Core Scientific also secured an additional 300 MW of power and acquired more than 200 acres of land.
5. Tempus AI Is Bringing AI Into Real-World Healthcare
Ticker: NASDAQ: TEM
Average Upside Potential: 41.04%
Tempus AI operates at the intersection of healthcare and artificial intelligence. On April 23, the company announced a partnership with the Keck School of Medicine of USC.
The collaboration is expected to impact more than 1.5 million annual patient visits across affiliated healthcare facilities. It focuses on clinical testing, clinical trial matching, care improvement pathways, and research development.
The company aims to use AI-driven diagnostics and data tools to improve patient outcomes and personalize care.
4. Nuvalent Is Racing Toward an FDA Decision
Ticker: NASDAQ: NUVL
Average Upside Potential: 41.11%
Nuvalent submitted an NDA to the FDA on April 7 for neladalkib, a treatment candidate for advanced ALK-positive non-small cell lung cancer in previously treated patients.
The filing came less than four years after the first clinical trial began. It is supported by ALKOVE-1 Phase 1 and 2 data, which showed anti-tumor activity, including in patients with brain metastases.
The company remains one of the more closely watched oncology development names on this list.
3. StandardAero Is a Fresh Public Company With Strong Industry Exposure
Ticker: NYSE: SARO
Average Upside Potential: 42.92%
StandardAero provides maintenance, repair, and overhaul services across commercial and military aerospace, business aviation, and industrial power markets.
On March 31, the company appointed Giovanni Spitale as President of its Business Aviation segment. He brings more than 30 years of leadership experience, including prior senior roles at Boeing, GE Aviation, Honeywell, and Davis Standard.
The company recently entered public markets, making it a newer name that many investors are still discovering.
2. ESAB Is Showing Confidence Despite Global Uncertainty
Ticker: NYSE: ESAB
Average Upside Potential: 44.76%
ESAB manufactures welding, cutting, gas control, and industrial productivity solutions.
On April 2, the company appointed R. Brent Jones as Chief Financial Officer, effective in early May. He brings more than 30 years of leadership experience and previously held senior finance roles at Avantor and Pall Corporation.
At the same time, ESAB reaffirmed its full-year 2026 outlook despite geopolitical volatility. That confidence has helped keep the company on investor watchlists.
1. GE HealthCare Has the Highest Upside Potential on This List
Ticker: NASDAQ: GEHC
Average Upside Potential: 48.83%
GE HealthCare ranks first based on the upside figures in the source material.
On April 29, the company reported Q1 2026 revenue of $5.1 billion, up 7.4%, with organic revenue growth of 2.9%. Organic orders rose 1.1%, while backlog reached $21.8 billion. Its book-to-bill ratio stood at 1.07.
The quarter also included the $2.3 billion acquisition of Intelerad, aimed at strengthening imaging technology capabilities.
GE HealthCare reported a net income margin of 7.6%, an adjusted EBIT margin of 13.5%, diluted EPS of $0.85, and adjusted EPS of $0.99.
The company reaffirmed its organic revenue growth guidance of 3.0% to 4.0%, though it lowered profit and free cash flow expectations due to inflation in memory chips, oil, and freight. Updated adjusted EPS guidance is $4.80 to $5.00, with free cash flow near $1.6 billion.
Final Take
This list shows that opportunities are spread across several sectors. Biotech companies offer regulatory catalysts. AI infrastructure firms are tied to the rising demand for compute. Healthcare names continue to benefit from steady long-term demand. Industrial companies remain relevant when execution stays strong.
No stock is guaranteed to rise, and analyst targets can change quickly. Still, these 10 names stand out because they combine measurable upside potential with real business developments that investors can track closely.
